661 results on '"Rustin, G"'
Search Results
102. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop☆
103. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings
104. Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
105. Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis
106. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
107. A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22
108. Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours
109. Polysomnography in Hospitalized Patients Using a Wireless Wide Area Network
110. SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
111. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
112. An assessment of mid-chemotherapy CT scanning as a predictor of a residual retroperitoneal mass in good prognosis metastatic teratoma of the testis
113. A phase Ib trial of combretastatin A- 4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer
114. Use of changes in CA125 doubling time to detect activity of cytostatic agents in women relapsing with ovarian carcinoma. Study 1 - tamoxifen
115. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies
116. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
117. RESPONSE: Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
118. OC12 MAGNETIC RESONANCE IMAGING (MRI) AND INTRAVITAL MICROSCOPY TO MEASURE TUMOUR VASCULAR MATURITY
119. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population
120. A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982
121. A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers
122. Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome
123. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
124. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
125. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
126. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
127. A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma
128. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours – a retrospective long-term follow-up study
129. A phase 1 study of tazarotene in adults with advanced cancer
130. AN AUTHORIZED CONTAINER PROGRAM AT THE NEVADA TEST SITE.
131. Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials
132. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital.
133. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
134. High Levels of hCG in Choriocarcinoma Can Result in Renal Failure and a False-Negative Pregnancy Test in Men
135. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
136. Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours
137. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
138. Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee
139. O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
140. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy
141. Gestational Trophoblastic Disease With Liver Metastases
142. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
143. Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role
144. Surveillance policy for stage I ovarian germ cell tumors.
145. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
146. Gestational trophoblastic disease with liver metastases: the Charing Cross experience
147. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.
148. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
149. Immunoglobulin Ihhibiting Reagent®: Evaluation of a New Method for Eliminating Spurious Elevations in CA125 Caused by HAMA
150. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.